南新制药
(688189)
| 流通市值：21.24亿 | | | 总市值：21.24亿 |
| 流通股本：2.74亿 | | | 总股本：2.74亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 389,076,108.51 | 529,023,183.42 | 644,597,429.05 | 665,760,897.54 |
| 应收票据及应收账款 | 428,454,171.37 | 504,056,510.08 | 522,706,466.81 | 559,906,023.28 |
| 其中：应收票据 | 532,310.5 | 305,513 | 81,913 | 15,944,236.8 |
| 应收账款 | 427,921,860.87 | 503,750,997.08 | 522,624,553.81 | 543,961,786.48 |
| 应收款项融资 | 928,842.83 | 5,011,488.22 | 28,623,041.99 | 27,128,199.72 |
| 预付款项 | 16,775,635.27 | 9,690,928.94 | 12,880,775.48 | 5,270,459.01 |
| 其他应收款合计 | 1,885,861.81 | 1,879,951.24 | 2,044,173.67 | 947,489.93 |
| 其中:应收利息 | - | - | 530,958.91 | - |
| 存货 | 67,051,501.23 | 41,384,600.6 | 31,399,170.09 | 28,416,002.16 |
| 其他流动资产 | 6,978,763.08 | 3,382,843.67 | 3,362,103.84 | 2,581,955.73 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 911,150,884.1 | 1,094,429,506.17 | 1,245,613,160.93 | 1,290,011,027.37 |
| 非流动资产: | | | | |
| 固定资产 | 171,700,405.14 | 176,584,110.91 | 181,422,978.89 | 184,895,382.43 |
| 在建工程 | 592,943.39 | 592,943.39 | 573,132.07 | 573,132.07 |
| 使用权资产 | 479,304.2 | 678,786.89 | 878,269.58 | 1,077,752.27 |
| 无形资产 | 133,116,642.82 | 136,839,086.84 | 140,561,530.87 | 124,284,348.67 |
| 开发支出 | 74,405,714.68 | 60,512,530.71 | 53,165,585.15 | 63,479,606.85 |
| 商誉 | 10,845,017.78 | 10,845,017.78 | 10,845,017.78 | 10,845,017.78 |
| 长期待摊费用 | 480,909.76 | 558,092.82 | 635,275.87 | 712,458.91 |
| 递延所得税资产 | 60,233,757.53 | 58,672,392.71 | 57,216,262.86 | 57,264,660.1 |
| 其他非流动资产 | 5,555,385.31 | 3,242,720 | 4,386,580 | 4,393,080 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 457,410,080.61 | 448,525,682.05 | 449,684,633.07 | 447,525,439.08 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,368,560,964.71 | 1,542,955,188.22 | 1,695,297,794 | 1,737,536,466.45 |
| 流动负债: | | | | |
| 短期借款 | 65,050,555.56 | 155,120,555.55 | 285,157,574.57 | 322,950,113.81 |
| 应付票据及应付账款 | 44,016,762.43 | 33,192,748.17 | 46,908,896.34 | 39,547,644.6 |
| 应付账款 | 44,016,762.43 | 33,192,748.17 | 46,908,896.34 | 39,547,644.6 |
| 合同负债 | 11,691,693.17 | 21,693,440.24 | 22,871,248.07 | 13,481,060.04 |
| 应付职工薪酬 | 5,135,221.93 | 8,010,059.71 | 6,311,901.64 | 7,067,519.5 |
| 应交税费 | 2,094,711.17 | 6,535,428.54 | 4,765,501.52 | 14,988,220.79 |
| 其他应付款合计 | 24,920,386.99 | 21,380,443.12 | 24,118,376.43 | 26,994,177.35 |
| 一年内到期的非流动负债 | 372,034.34 | 536,115.46 | 536,115.46 | 710,687.48 |
| 其他流动负债 | 478,875.2 | 2,490,687.41 | - | 3,702,537.81 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 153,760,240.79 | 248,959,478.2 | 390,669,614.03 | 429,441,961.38 |
| 非流动负债: | | | | |
| 租赁负债 | 695,500.53 | 724,582.53 | 917,745.65 | 936,336.75 |
| 递延收益 | 3,075,000 | 3,150,000 | 3,225,000 | 3,300,000 |
| 递延所得税负债 | 1,373,942.26 | 1,426,537.69 | 1,479,133.13 | 1,531,728.57 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 5,144,442.79 | 5,301,120.22 | 5,621,878.78 | 5,768,065.32 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 158,904,683.58 | 254,260,598.42 | 396,291,492.81 | 435,210,026.7 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 274,400,000 | 274,400,000 | 274,400,000 | 274,400,000 |
| 资本公积 | 1,175,415,514.58 | 1,175,415,514.58 | 1,175,415,514.58 | 1,175,415,514.58 |
| 减:库存股 | 9,998,136.25 | 7,997,384.37 | 7,997,384.37 | - |
| 盈余公积 | 20,100,414.53 | 20,100,414.53 | 20,100,414.53 | 20,100,414.53 |
| 未分配利润 | -223,635,962.53 | -156,247,362.39 | -148,033,393.96 | -151,799,902.51 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,236,281,830.33 | 1,305,671,182.35 | 1,313,885,150.78 | 1,318,116,026.6 |
| 少数股东权益 | -26,625,549.2 | -16,976,592.55 | -14,878,849.59 | -15,789,586.85 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,209,656,281.13 | 1,288,694,589.8 | 1,299,006,301.19 | 1,302,326,439.75 |
| 负债和股东权益合计 | 1,368,560,964.71 | 1,542,955,188.22 | 1,695,297,794 | 1,737,536,466.45 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-30 | 2024-03-26 |
| 审计意见(境内) | | | | 标准无保留意见 |